Patents by Inventor Hans Gühring
Hans Gühring has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11813307Abstract: The present invention relates to polypeptides binding Aggrecan as well as ADAMTS5 and/or MMP13, more in particular to polypeptides that comprise or essentially consist of immunoglobulins binding Aggrecan as well as immunoglobulins binding ADAMTS5 and/or immunoglobulins binding MMP13 (also referred to herein as “polypeptides of the invention”, and “immunoglobulin(s) of the invention”, respectively).Type: GrantFiled: June 4, 2018Date of Patent: November 14, 2023Assignees: MERCK PATENT GMBH, ABLYNX NVInventors: Soren Steffensen, Gerald Beste, Hans Guehring, Lars Toleikis, Christoph Ladel, Sven Lindemann, Roland Kellner, Ralf Guenther
-
Publication number: 20230312694Abstract: The present invention relates to immunoglobulins that specifically bind Aggrecan and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of Aggrecan.Type: ApplicationFiled: December 23, 2022Publication date: October 5, 2023Applicants: Ablynx N.V., Merck Patent GmbHInventors: Soren Steffensen, Gerald Beste, Guy Hermans, Hans Gühring, Christoph Ladel, Lars Toleikis
-
Publication number: 20230258659Abstract: The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during treatment of a cartilage disorder. It relates more particularly to specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used as biomarkers for the diagnosis, pre-treatment of patients and during therapy of cartilage disorders. The invention can be used in predicting the response to an FGF-18 compound treatment, before starting the treatment or during the treatment. It could be used for selecting/identifying subjects to be treated according to specific doses and/or dosing regimens by intra-articular administration of an FGF-18 compound. The use of these biomarkers in diagnostics could result in increased benefit and reduced risk-benefit ratio in subjects.Type: ApplicationFiled: September 1, 2022Publication date: August 17, 2023Applicant: MERCK PATENT GMBHInventors: Christoph H. LADEL, Hans GUEHRING, Anne-Christine BAY-JENSEN, Morten KARSDAL, Per QVIST
-
Publication number: 20230251271Abstract: The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during treatment of a cartilage disorder. The present invention more particularly relates to specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used for the diagnosis and treatment of cartilage disorders. The invention further discloses specific proteins that are related to cartilage response to an FGF-18 compound treatment as well as diagnostic tools and kits based on their expression profile. Thus, the invention can be used in predicting the response to an FGF-18 compound treatment, before starting the treatment with FGF-18 or during the treatment. It could be used for selecting/identifying subjects to be treated by intra-articular administration of an FGF-18 compound. The use of these biomarkers in diagnostics could result in increased benefit and reduced risk in subjects.Type: ApplicationFiled: September 7, 2022Publication date: August 10, 2023Applicant: MERCK PATENT GMBHInventors: Christoph H. LADEL, Hans GUEHRING, Anne-Christine BAY-JENSEN, Morten KARSDAL, Per QVIST
-
Publication number: 20230210948Abstract: The present disclosure relates to methods related to the treatment of IgA nephropathy. More specifically, the present disclosure relates to methods for treating a patient having IgA nephropathy (IgAN), to methods for reducing the serum Gd-IgA1 level in a patient having IgA nephropathy (IgAN), to methods for reducing the proteinuria in a patient having IgA nephropathy, to methods for reducing the serum Gd-IgA1 level and the proteinuria in a patient having IgA nephropathy, and further related disclosure.Type: ApplicationFiled: December 2, 2022Publication date: July 6, 2023Inventors: Stephen Daniel WAX, Roberto BASSI, Hans GUEHRING, Christopher TEHLIRIAN, Amy Hui-Chien KAO
-
Patent number: 11603401Abstract: The present invention relates to immunoglobulins that specifically bind Aggrecan and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of Aggrecan.Type: GrantFiled: June 4, 2018Date of Patent: March 14, 2023Assignees: Ablynx N.V., Merck Patent GmbHInventors: Soren Steffensen, Gerald Beste, Guy Hermans, Hans Gühring, Christoph Ladel, Lars Toleikis
-
Publication number: 20220378981Abstract: The present invention provides a new method related to regenerative medicine for the treatment of cartilage disorders, osteoarthritis and cartilage injury in particular. More particularly, it relates to an FGF-18 compound for use in tissue engineering and graft procedures, such as osteochondral or cartilage transplantation or autologous chondrocyte implantation (ACI).Type: ApplicationFiled: June 16, 2022Publication date: December 1, 2022Inventors: Christoph H. LADEL, Hans GUEHRING, Anne GIGOUT
-
Patent number: 11513128Abstract: The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during treatment of a cartilage disorder. The present invention more particularly relates to specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used for the diagnosis and treatment of cartilage disorders. The invention further discloses specific proteins that are related to cartilage response to an FGF-18 compound treatment as well as diagnostic tools and kits based on their expression profile. Thus, the invention can be used in predicting the response to an FGF-18 compound treatment, before starting the treatment with FGF-18 or during the treatment. It could be used for selecting/identifying subjects to be treated by intra-articular administration of an FGF-18 compound. The use of these biomarkers in diagnostics could result in increased benefit and reduced risk in subjects.Type: GrantFiled: September 28, 2018Date of Patent: November 29, 2022Assignee: MERCK PATENT GMBHInventors: Christoph H. Ladel, Hans Guehring, Anne-Christine Bay-Jensen, Morten Karsdal, Per Qvist
-
Patent number: 11467169Abstract: The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during treatment of a cartilage disorder. It relates more particularly to specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used as biomarkers for the diagnosis, pre-treatment of patients and during therapy of cartilage disorders. The invention can be used in predicting the response to an FGF-18 compound treatment, before starting the treatment or during the treatment. It could be used for selecting/identifying subjects to be treated according to specific doses and/or dosing regimens by intra-articular administration of an FGF-18 compound. The use of these biomarkers in diagnostics could result in increased benefit and reduced risk-benefit ratio in subjects.Type: GrantFiled: September 28, 2018Date of Patent: October 11, 2022Assignee: MERCK PATENT GMBHInventors: Christoph H. Ladel, Hans Guehring, Anne-Christine Bay-Jensen, Morten Karsdal, Per Qvist
-
Publication number: 20220289860Abstract: The present invention relates to immunoglobulins that bind ADAMTS5 and more in particular to polypeptides, that comprise or essentially consist of one or more such immunoglobulins. The invention also relates to constructs comprising such immunoglobulins, such as immunoglobulin single variable domains (ISVDs) or polypeptides as well as nucleic acids encoding such immunoglobulins or polypeptides; to methods for preparing such immunoglobulins, polypeptides and constructs; to host cells expressing or capable of expressing such immunoglobulins or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such immunoglobulins, polypeptides, constructs, nucleic acids and/or host cells; and to uses of immunoglobulins, polypeptides, constructs, nucleic acids, host cells and/or compositions, in particular for prophylactic and/or therapeutic purposes, such as the prophylactic and/or therapeutic purposes mentioned herein.Type: ApplicationFiled: January 19, 2022Publication date: September 15, 2022Inventors: Marie-Ange Buyse, Guy Hermans, Sven Lindemann, Hans Guehring, Ralf Guenther, Roland Kellner
-
Publication number: 20220184180Abstract: The invention pertains to active compounds, in particular FGF-18 compounds, for use in the treatment of patients affected with a cartilage disorder, preferably osteoarthritis (OA), in particular for the treatment of patients who are at risk of rapid progression of the disorder.Type: ApplicationFiled: February 7, 2020Publication date: June 16, 2022Inventors: CHRISTOPH H. LADEL, HANS GUEHRING
-
Publication number: 20220089703Abstract: The present invention relates to immunoglobulins that specifically bind Aggrecan and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of Aggrecan.Type: ApplicationFiled: June 4, 2018Publication date: March 24, 2022Applicants: Ablynx N.V., Merck Patent GmbHInventors: Soren Steffensen, Gerald Beste, Guy Hermans, Hans Gühring, Christoph Ladel, Lars Toleikis
-
Patent number: 11261260Abstract: The present invention relates to immunoglobulins that bind ADAMTS5 and more in particular to polypeptides, that comprise or essentially consist of one or more such immunoglobulins. The invention also relates to constructs comprising such immunoglobulins, such as immunoglobulin single variable domains (ISVDs) or polypeptides as well as nucleic acids encoding such immunoglobulins or polypeptides; to methods for preparing such immunoglobulins, polypeptides and constructs; to host cells expressing or capable of expressing such immunoglobulins or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such immunoglobulins, polypeptides, constructs, nucleic acids and/or host cells; and to uses of immunoglobulins, polypeptides, constructs, nucleic acids, host cells and/or compositions, in particular for prophylactic and/or therapeutic purposes, such as the prophylactic and/or therapeutic purposes mentioned herein.Type: GrantFiled: June 4, 2018Date of Patent: March 1, 2022Assignees: Merck Patent GmbH, ABLYNX NVInventors: Marie-Ange Buyse, Guy Hermans, Sven Lindemann, Hans Guehring, Ralf Guenther, Roland Kellner
-
Publication number: 20220047674Abstract: The present invention relates to pharmacogenetics, more specifically to strategies involving biomarkers associated with the clinical response to a compound before or during treatment of a cartilage disorder, such as osteoarthritis. The present invention more particularly relates to the combination of JSW measurements and level of specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used in strategies such as patients' enrichment in clinical trials, patients' selection strategy before or during treatment or for adapting the treatment of a patient in the frame of treatments for cartilage disorder, such as osteoarthritis.Type: ApplicationFiled: September 9, 2019Publication date: February 17, 2022Inventors: CHRISTOPH H. LADEL, HANS GUEHRING, ANNE-CHRISTINE BAY-JENSEN, MORTEN KARSDAL, PER QVIST
-
Publication number: 20210231681Abstract: The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during treatment of a cartilage disorder. The present invention more particularly relates to specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used for the diagnosis and treatment of cartilage disorders. The invention further discloses specific proteins that are related to cartilage response to an FGF-18 compound treatment as well as diagnostic tools and kits based on their expression profile. Thus, the invention can be used in predicting the response to an FGF-18 compound treatment, before starting the treatment with FGF-18 or during the treatment. It could be used for selecting/identifying subjects to be treated by intra-articular administration of an FGF-18 compound. The use of these biomarkers in diagnostics could result in increased benefit and reduced risk in subjects.Type: ApplicationFiled: September 28, 2018Publication date: July 29, 2021Inventors: CHRISTOPH H. LADEL, HANS GUEHRING, ANNE-CHRISTINE BAY-JENSEN, MORTEN KARSDAL, PER QVIST
-
Publication number: 20210231680Abstract: The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during treatment of a cartilage disorder. It relates more particularly to specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used as biomarkers for the diagnosis, pre-treatment of patients and during therapy of cartilage disorders. The invention can be used in predicting the response to an FGF-18 compound treatment, before starting the treatment or during the treatment. It could be used for selecting/identifying subjects to be treated according to specific doses and/or dosing regimens by intra-articular administration of an FGF-18 compound. The use of these biomarkers in diagnostics could result in increased benefit and reduced risk-benefit ratio in subjects.Type: ApplicationFiled: September 28, 2018Publication date: July 29, 2021Inventors: CHRISTOPH H. LADEL, HANS GUEHRING, ANNE-CHRISTINE BAY-JENSEN, MORTEN KARSDAL, PER QVIST
-
Publication number: 20210115117Abstract: The present invention relates to immunoglobulins that specifically bind Aggrecan and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of Aggrecan.Type: ApplicationFiled: June 4, 2018Publication date: April 22, 2021Applicants: Ablynx N.V., Merck Patent GmbHInventors: Soren Steffensen, Gerald Beste, Guy Hermans, Hans Gühring, Christoph Ladel, Lars Toleikis
-
Publication number: 20210008160Abstract: The present invention relates to polypeptides binding Aggrecan as well as ADAMTS5 and/or MMP13, more in particular to polypeptides that comprise or essentially consist of immunoglobulins binding Aggrecan as well as immunoglobulins binding ADAMTS5 and/or immunoglobulins binding MMP13 (also referred to herein as “polypeptides of the invention”, and “immunoglobulin(s) of the invention”, respectively).Type: ApplicationFiled: June 4, 2018Publication date: January 14, 2021Applicants: Merck Patent GmbH, ABLYNX NVInventors: Soren STEFFENSEN, Gerald BESTE, Hans GUEHRING, Lars TOLEIKIS, Christoph LADEL, Sven LINDEMANN, Roland KELLNER, Ralf GUENTHER
-
Publication number: 20200317802Abstract: The present invention relates to immunoglobulins that bind ADAMTSS and more in particular to polypeptides, that comprise or essentially consist of one or more such immunoglobulins. The invention also relates to constructs comprising such immunoglobulins, such as immunoglobulin single variable domains (ISVDs) or polypeptides as well as nucleic acids encoding such immunoglobulins or polypeptides; to methods for preparing such immunoglobulins, polypeptides and constructs; to host cells expressing or capable of expressing such immunoglobulins or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such immunoglobulins, polypeptides, constructs, nucleic acids and/or host cells; and to uses of immunoglobulins, polypeptides, constructs, nucleic acids, host cells and/or compositions, in particular for prophylactic and/or therapeutic purposes, such as the prophylactic and/or therapeutic purposes mentioned herein.Type: ApplicationFiled: June 4, 2018Publication date: October 8, 2020Applicants: Merck Patent GmbH, ABLYNX NVInventors: Marie-Ange BUYSE, Guy HERMANS, Sven LINDEMANN, Hans GUEHRING, Ralf GUENTHER, Roland KELLNER
-
Publication number: 20200222454Abstract: The present invention relates to the treatment of osteoarthritic pain and to the slowing down of the structural osteoarthritis progression in a patient having osteoarthritis. More particularly, it relates to a physiological compound for use according to particular treatment regimens. Specifically, it concerns a treatment scheme comprising weekly administration for three or four times of a physiological compound per treatment cycle.Type: ApplicationFiled: September 26, 2018Publication date: July 16, 2020Inventors: CHRISTOPH H. LADEL, HANS GUEHRING